Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
It's Jobs Week Already? Plus Q4 Reports from MSFT, GOOGL, AAPL, AMZN
10:46am, Monday, 29'th Jan 2024
This week starts slow, but we'll end it with a full-fledged Jobs Week for February. Plus more than half the Magnificent 7 reports earnings.
Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?
09:26am, Monday, 29'th Jan 2024
Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on the f
Pfizer's earnings growth trade at a deep discount, suddenly a buy
07:01am, Monday, 29'th Jan 2024
The defensive names, characterized by their immunity to the business cycle, in the market could soon see an inflow of investment dollars not seen since the last wave of the business cycle. This time,
Where Will Pfizer Be in 10 Years?
05:05am, Sunday, 28'th Jan 2024
Pfizer has reached a transition point as sales of its top products decline. But the company is completing its biggest string of new product launches, a move to spur a new phase of growth.
3 Dividend Stocks to Buy and Hold for Long-Term Income in 2024
01:39pm, Friday, 26'th Jan 2024
2024 is set to be one of the most unpredictable years in recent memory. A historic election year, geopolitical conflicts and their spillover effects and an uncertain economic backdrop are all in the c
What You Need To Know Ahead of Pfizer's Earnings on Tuesday
12:50pm, Friday, 26'th Jan 2024
Analysts are projecting another difficult quarter for Pfizer Inc. (PFE) in which the company likely suffered a steep drop in revenue as demand for its COVID-19 products declined.
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
12:01pm, Friday, 26'th Jan 2024
Healthcare stocks trudged through what was a terrible 2023 for the sector. While the S&P 500 rose by 24% during 2023, the healthcare sector managed paltry returns of 0.3%.
3 Stocks to Sell Before Their Earnings Reports Disappoint in 2024
02:21pm, Thursday, 25'th Jan 2024
Earnings season can have an outsized impact on a company's share price, which means considering stocks to sell before earnings reports are released. Netflix (NASDAQ: NFLX ) reports great subscriber gr
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
01:06pm, Thursday, 25'th Jan 2024
Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedu
Curious about Pfizer (PFE) Q4 Performance? Explore Wall Street Estimates for Key Metrics
10:20am, Thursday, 25'th Jan 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quar
5 top healthcare stocks for earnings growth in 2024
07:09am, Thursday, 25'th Jan 2024
Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp.
How Does Pfizer Fit Into a Well-Diversified Portfolio?
06:00am, Thursday, 25'th Jan 2024
Modern portfolio theory dictates that investors should own a variety of unrelated asset types. Pfizer, a top-shelf pharma stock, has attributes that could allow it to serve a variety of roles.
System1 gains as Tesco, Pfizer marketing deals aid revenue jump
08:27am, Wednesday, 24'th Jan 2024
System1 Group (AIM:SYS1) PLC climbed 23% on Wednesday as the marketing firm said recent deals with the likes of Tesco, Pfizer and M&S meant full-year expectations would be smashed. Some 60 new clients
Pfizer (PFE) to Report Q4 Earnings: Here's What to Expect
07:41am, Wednesday, 24'th Jan 2024
Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.
Why Pfizer Is a Much Better Stock Than You Might Think
05:50am, Wednesday, 24'th Jan 2024
Pfizer faces declining demand for its COVID-19 products and upcoming patent expirations for several top-selling products. However, the company's future appears brighter than its current situation migh
